TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23070146
Drug: Nilotinib 400
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib 400 mg alone
Study: 20699330
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered chemotherapy
Study: 16760903
Drug: Electrolyzed-reduced water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrolyzed-reduced water (ERW) treatment for 6 months
Study: 16760903
Drug: Vitamin E-coated
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E-coated dialyzer treatment
Study: 25407026
Drug: Hartmann's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hartmann's solution (HS)
Study: 29144182
Drug: Plasma-Lyte 148
Normalized name: Plasma-lyte 148
DrugBank: Gluconic Acid (DB13180)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma-Lyte 148 (PL) and Hartmann's solution (HS)
Study: 23868538
Drug: Volume Guarantee
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume Guarantee (VG) ventilation (Vt=5 mL/kg, PEEP=5 cmH2O)
Study: 12002664
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol maleate ophthalmic gel-forming solution QD
Study: 7791837
Drug: Conservative transfusion
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative transfusion regimen (designed to increase hemoglobin level to 10 g per deciliter)
Study: 2189906
Drug: R 68
Normalized name: afoxolaner 68 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: R 68 151 2% ointment
Study: 21039597
Drug: Vehicle ointment
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle ointment
Study: 74662
Drug: gamma-globulin concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: gamma-globulin concentrate as adjunctive therapy
Study: 31313270
Drug: BAY 94-9027
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 94-9027 (extended half-life factor VIII replacement therapy) infused once every 7 days, once every 5 days, or twice weekly
Study: 24774590
Drug: Conventional management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional management of heart failure and an individualized nutritional intervention (optimization of diet, specific recommendations, and nutritional supplements if necessary)
Study: 15748694
Drug: Ultrasound self-therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound self-therapy
Study: 12452946
Drug: Chewable antacid
Normalized name: CALCIUM CARBONATE 500 mg ORAL TABLET, CHEWABLE [CALCIUM CARBONATE CHEWABLE ANTACID]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewable antacid tablets (1000 mg CaCO3)
Study: 12452946
Drug: Active chewable
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active chewable antacid and gums
Study: 7535996
Drug: 200‐mL boluses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200‐mL boluses of a 6% hydroxyethyl starch solution
Study: 28756042
Drug: Continue Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue Patch
Study: 28756042
Drug: Discontinue Patch
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinue Patch
Study: 27117056
Drug: Bevacizumab (BEV)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (BEV) continuation as a single agent
Study: 27117056
Drug: No BEV
Approvals — FDA: no, EMA: no, PMDA: no
Description: No BEV (treatment holidays)
Study: 11789299
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement containing 67% omega-3 fatty acids (185 mg EPA and 465 mg DHA) in a spread form, 7 grams daily for 12 weeks.
Study: 8358459
Drug: Intramuscular injections
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections
Study: 2143300
Drug: Akne-Mycyna (1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Akne-Mycyna (1% erythromycin), applied twice daily for at least 3 weeks
Study: 6112131
Drug: Benzodiazepine anxiolytics
Normalized name: 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
DrugBank: Nitrazepam (DB01595)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepine anxiolytics
Study: 30149997
Drug: Ultra-low-dose CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose CT (100Sn kVp, 70 mAs)
Study: 30149997
Drug: Standard-dose CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose CT (110 kVp, 50 mAs)
Study: 30149997
Drug: Ultra-low-dose CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose CT
Study: 9024711
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg
Study: 19451435
Drug: Imatinib (IM)
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib (IM) 400 mg daily
Study: 16974199
Drug: 0.6 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 g/kg ethanol
Study: 11273587
Drug: High-dose leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose leucovorin (175 mg) with fluorouracil (370 mg/m2)
Study: 11273587
Drug: Low-dose leucovorin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose leucovorin (25 mg) with fluorouracil (370 mg/m2)
Study: 11273587
Drug: Levamisole (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (50 mg) with fluorouracil and leucovorin
Study: 11273587
Drug: Weekly treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly treatment regimen
Study: 11273587
Drug: Monthly treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly treatment regimen
Study: 7834324
Drug: Terfenadine 120
Normalized name: terfenadine 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine 120 mg/day for 21 days
Study: 2024862
Drug: Aerosol pentamidine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol pentamidine, 60 mg per dose, delivered via ultrasonic nebulizer, 5 doses over 14 days followed by maintenance of one dose every 2 weeks.
Study: 2024862
Drug: Placebo, delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, delivered via ultrasonic nebulizer, 5 doses over 14 days followed by maintenance of one dose every 2 weeks.
Study: 7416269
Drug: Hemodialysis, twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemodialysis, twice weekly for 10 weeks
Study: 7416269
Drug: Sham dialysis,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham dialysis, twice weekly for 10 weeks
Study: 6697071
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml normal saline
Study: 28866763
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (StnTx: two servings milk and milk products/day; meet PA guidelines plus weight-bearing PA three times/week)
Study: 28866763
Drug: Modified treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified treatment (ModTx: four servings milk and milk products/day; meet PA guidelines plus daily weight-bearing PA)
Study: 23578004
Drug: Acetazolamide 250
Normalized name: acetazolamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide 250 mg three times a day for 5 days
Study: 16939522
Drug: Novel matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel matrix transdermal delivery system of fentanyl
Study: 16939522
Drug: Durogesic reservoir
Normalized name: Dologesic
DrugBank: Phenyltoloxamine (DB11160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Durogesic reservoir formulation
Study: 11485582
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of butylcyanoacrylate
Study: 7522283
Drug: Amlodipine (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5-10 mg o.d.)
Study: 7603076
Drug: Enalapril (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10-20 mg o.d.)
Study: 3250868
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ferrous sulphate
Study: 3250868
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg riboflavin and 150 mg ascorbic acid
Study: 23909402
Drug: L-carnitine (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (900 mg/day)
Study: 20962342
Drug: Dilute diesel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilute diesel exhaust (particle concentration 300 μg/m³)
Study: 18704484
Drug: BCAA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA supplementation (1.7 MJ day(‐1) high-protein supplement composed of 50% valine, 35% leucine, and 15% isoleucine)
Study: 17039422
Drug: metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin plus liraglutide
Study: 1486457
Drug: Dopaminergic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopaminergic therapy (levodopa, bromocriptine)
Study: 20708714
Drug: Micronutrient and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient and antioxidant preparation
Study: 20708714
Drug: Standard multivitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard multivitamins (identical appearing recommended daily allowance multivitamin and mineral preparation)
Study: 16280697
Drug: HAART plus
Normalized name: Tri-Heart Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART plus subcutaneous IL-2
Study: 16280697
Drug: HAART plus
Normalized name: Tri-Heart Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART plus intravenous IL-2
Study: 12184060
Drug: Eprosartan (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan (600 mg/day)
Study: 12118904
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of enalapril (10 mg/day) and eprosartan (300 mg/day)
Study: 10468077
Drug: Chewed buffered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewed buffered aspirin tablet (325 mg)
Study: 10468077
Drug: Swallowed whole
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swallowed whole buffered aspirin tablet (325 mg)
Study: 10468077
Drug: Buffered aspirin
Normalized name: Buffered Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buffered aspirin solution (Alka Seltzer)
Study: 462483
Drug: Single test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single test dose of irradiation
Study: 462483
Drug: Fractionated test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractionated test dose of irradiation
Study: 25736134
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (20 mg atorvastatin calcium)
Study: 9709756
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac sodium 0.1% (Voltaren)
Study: 9709756
Drug: Prednisolone sodium
Normalized name: Prednisolone Sodium Phosphate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone sodium phosphate 1% ophthalmic solution
Study: 7977070
Drug: Sotalol (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (240 mg twice daily for 7 days)
Study: 7977070
Drug: Amiodarone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (600 mg 3 times daily for 10 days)
Study: 2535309
Drug: Phentolamine, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentolamine, 3 mg
Study: 26508645
Drug: Breast augmentation
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast augmentation in the subglandular plane
Study: 17351806
Drug: Gabexate mesylate
Normalized name: mesylate
DrugBank: Gabexate (DB12831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabexate mesylate (600 mg)
Study: 12605430
Drug: Intra-operative Photofrin-photodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-operative Photofrin-photodynamic therapy (PDT)
Study: 7543038
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg morphine
Study: 10702454
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg morphine
Study: 8447205
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% with epinephrine, 20 ml, intermittent 8-hourly bolus injections
Study: 2943816
Drug: Recombinant hepatitis
Normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hepatitis B vaccine (HBX‐R) administered IM at 10 micrograms, 3 doses (0, 1 month, 6 months)
Study: 2943816
Drug: Plasma-derived hepatitis
Normalized name: Haptoglobulin 1/1 (Plasma Derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma-derived hepatitis B vaccine (H‐B‐VAX) administered IM at 20 micrograms, 3 doses (0, 1 month, 6 months)
Study: 31560577
Drug: Sports medicine
Normalized name: Mueller Sports Medicine Compression Glove
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sports medicine physicians
Study: 31560577
Drug: Family/internal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family/internal medicine physicians
Study: 29446377
Drug: Tiotropium bromide
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiotropium bromide inhalation powder combined with fluticasone propionate aerosol (group D)
Study: 27431995
Drug: Daily trimethoprim-sulfamethoxazole
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily trimethoprim-sulfamethoxazole (TS) prophylaxis
Study: 27431995
Drug: Weekly chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly chloroquine (CQ) prophylaxis
Study: 27431995
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of standard of care TS prophylaxis
Study: 24615137
Drug: Artesunate (AS)
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate (AS) in combination with sulfadoxine/pyrimethamine (SP)
Study: 9583331
Drug: Day treatment
Normalized name: Pharmacist Clotrimazole 3 Day Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day treatment
Study: 10389026
Drug: B-vitamins (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-vitamins (400 micrograms folic acid + 1.65 mg pyridoxine + 3 micrograms cyanocobalamin)
Study: 9060347
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (current/daily routines)
Study: 26352814
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin
Study: 1650406
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Low-molecular-weight heparin and Unfractionated heparin)
Study: 1650406
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin and Unfractionated heparin
Study: 12452235
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg epidural morphine
Study: 7104806
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg epidural morphine
Study: 7104806
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg (saline control)
Study: 27409799
Drug: CHX solution
Normalized name: chlorhexidine gluconate Topical Solution [CHX Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHX solution with SRP
Study: 27409799
Drug: CHX gel
Normalized name: chlorhexidine gluconate Topical Solution [CHX Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHX gel with SRP
Study: 21109344
Drug: Silodosin 8
Normalized name: silodosin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silodosin 8 mg
Study: 31554005
Drug: Naftopidil 75
Normalized name: Naftopidil
DrugBank: Naftopidil (DB12092)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Naftopidil 75 mg
Study: 22929677
Drug: Detralex (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detralex (1,000 mg daily for 2 weeks prior and 4 weeks after endovascular treatment)
Study: 22929677
Drug: Conventional compression
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional compression therapy (compression bandages or medicinal knitted fabric)
Study: 15663066
Drug: Message campaign
Approvals — FDA: no, EMA: no, PMDA: no
Description: Message campaign about hand hygiene and availability of gel hand sanitizer
Study: 12858132
Drug: Topiramate (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (initial dose of 25 mg/day to a target dose of 100 mg BID)
Study: 10235193
Drug: Bismuth subsalicylate
Normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subsalicylate (2 tablets of Pepto-Bismol, positive control)
Study: 9074893
Drug: Paracetamol tablets
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol tablets (two lots)
Study: 1751620
Drug: MCPP (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCPP (0.25 mg/kg)
Study: 7047172
Drug: Metergoline 4
Normalized name: metergoline 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metergoline 4 mg tid for 7 days
Study: 7047172
Drug: Bromocriptine 2.5
Normalized name: bromocriptine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine 2.5 mg bid for 7 days
Study: 7047172
Drug: Metergoline (continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metergoline (continued treatment for 7 days)
Study: 7047172
Drug: Bromocriptine (continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (continued treatment for 7 days)
Study: 21993890
Drug: High sodium
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High sodium intake (300 mmol sodium/day; 17.5 g salt/day)
Study: 21993890
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium intake (30 mmol sodium/day; 1.8 g salt/day)
Study: 18685353
Drug: Lidocaine patches
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Patches]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine patches
Study: 11145439
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) induction treatment
Study: 11145439
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) maintenance treatment
Study: 2857610
Drug: Guanfacine (alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine (alpha 2‐agonist)
Study: 2857610
Drug: Idazoxan (alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idazoxan (alpha 2‐antagonist)
Study: 22950522
Drug: GLPG0259 single
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG0259 single ascending doses (1.5-150 mg)
Study: 22950522
Drug: GLPG0259 multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG0259 multiple doses (20 and 50 mg once daily)
Study: 22950522
Drug: GLPG0259 multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG0259 multiple doses (25-75 mg once daily for 14 days)
Study: 22950522
Drug: GLPG0259 solid
Normalized name: CORYDALIS SOLIDA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG0259 solid dosage form
Study: 17511187
Drug: Intermittent intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent intravenous pethidine
Study: 10513040
Drug: Evidence-based medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based medicine in treating coronary artery disease (CAD)
Study: 2126726
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release aspirin 50 mg
Study: 2126726
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release aspirin 100 mg
Study: 2126726
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release aspirin 5 mg
Study: 2126726
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release aspirin 10 mg
Study: 2126726
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release aspirin 25 mg
Study: 2126726
Drug: Soluble aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble aspirin 300 mg
Study: 2126726
Drug: Soluble aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble aspirin 50 mg
Study: 2126726
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and glycine formulation 100 mg
Study: 2126726
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release aspirin doses above 100 mg
Study: 2126726
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release aspirin doses of 50 mg and below
Study: 30865629
Drug: Small-quantity lipid-based
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-quantity lipid-based nutrient supplements (SQ-LNS) given to mothers and children during the first 1,000 days
Study: 27919901
Drug: CD101 IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD101 IV 50 mg
Study: 27919901
Drug: CD101 IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD101 IV 100 mg (once weekly for 2 weeks)
Study: 27919901
Drug: CD101 IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD101 IV 200 mg (once weekly for 2 weeks)
Study: 27919901
Drug: CD101 IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD101 IV 400 mg (once weekly for 3 weeks)
Study: 25145377
Drug: Varenicline 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline 2 mg single dose